Home » Eutropics Gets $1.7M in NCI Funds for PGx Tests

Eutropics Gets $1.7M in NCI Funds for PGx Tests

Sep 20, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Eutropics Pharmaceuticals has received two new Small Business Innovation Research award contracts totaling $1.7 million from the National Cancer Institute to fund development of two biomarker-based companion diagnostic assays for use in cancer treatment.

Eutropics has signed a phase II contract valued at $1.5 million to commercially develop its diagnostic assay aimed at multiple myeloma patient management, and a $200,000 phase I contract to develop a profiling diagnostic assay aimed at guiding therapies for patients with acute myelogenous leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

What's Popular?

In Diagnostics

  1. Cancer Genetics Q2 Revenues Down 6 Percent; Acquires VivoPharm for $12M

  2. CareDx Q2 Revenues Up 12 Percent

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.